arrow
H

Halfdan Sørbye

Haukeland University Hospital
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data

癌胚抗原flare在奥沙利铂为基础的化疗下预测微卫星稳定型转移性结直肠癌中尼鲁单抗的获益——METIMMOX试验数据的回顾性分析

2026-05-140
OAAI
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer

奥沙利铂诱导的纳武利尤单抗应答性探索性生物标志物在转移性微卫星稳定结直肠癌中的应用

2026-02-230
OAAI
Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

163转移性结直肠神经内分泌癌的分子临床特征和治疗结果与结直肠腺癌的比较

2026-02-050
OAAI
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts
2025-10-210
OAAI
Association rule mining of clinical and biomarker data in neuroendocrine tumors: A prospective study on disease progression

神经内分泌肿瘤的临床数据和生物标志物数据的关联规则挖掘:关于疾病进展的一项前瞻性研究

2025-08-140
OAAI
Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract

神经内分泌肿瘤(NEN)中的争议:ENETS关于胃肠胰道G3分化良好的神经内分泌肿瘤患者治疗立场声明

2025-08-090
OAAI
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

更正:特征和治疗结局——一项前瞻性队列研究,纳入639例晚期高级别消化道神经内分泌肿瘤(NET G3和NEC)。NORDIC NEC 2研究

2025-07-140
OAAI
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

639例高级别消化道神经内分泌肿瘤(NET G3和NEC)前瞻性队列的特征及治疗效果:NORDIC NEC 2研究

2025-05-170
OA
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

转移性微卫星稳定的BRAF V600E结直肠癌对基于奥沙利铂的一线化疗和免疫检查点阻断的完全反应

2024-06-280
OA
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
2024-03-220
PRE
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer - A post-hoc exploratory analysis of the randomized NORDIC9-studye

BRAFV600E突变对易受伤害的老年转移性结直肠癌患者的生存和治疗效果的影响-随机NORDIC9-studye的事后探索性分析

2024-03-010
OA